Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma.

Olivier Hermine; Hervé Dombret; Joel Poupon; Bertrand Arnulf; Francois Lefrère; Phillippe Rousselot; Gandhi Damaj; Richard Delarue; Jean Paul Fermand; Jean Claude Brouet

doi:10.1038/sj.thj.6200374

Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma.

NobleID: NI0P59W21R81S89
Persistent link: https://nobleid.org/ark:/48914/w1/20260515/CCEEC86F

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/CCEEC86F.svg?ark=w1%2F20260515%2FCCEEC86F&value=id)](https://nobleid.org/work/w1/20260515/CCEEC86F)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma.

NobleID: NI0P59W21R81S89
Persistent link: https://nobleid.org/ark:/48914/w1/20260515/CCEEC86F

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/CCEEC86F.svg?ark=w1%2F20260515%2FCCEEC86F&value=id)](https://nobleid.org/work/w1/20260515/CCEEC86F)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work